Menu Menu

News

Featured
COVID-19 Research Pipeline

137,915

Registered/ Published

4,281

Registered

658

Published

6,015

Registered
As at 27 May 2022
FILTERED BY > Disease-modifying treatments Clear filter

I’ve tested positive for COVID-19? What treatments are available?

9 March, 2022
  With several new drug treatments for people with mild COVID-19 now available, it can be tricky to know what your options are should you test positive to COVID-19. Taskforce directors Steve McGloughlin and Tari Turner, together with Panel co-chairs Bridget Barber and Joshua Davis explain who's at risk of disease progression, what the treatment options are, and who may...
Explainer

Communique #55

17 December, 2021
Click for the latest Taskforce news:
Communique

Communique #50

29 September, 2021
WEEK IN REVIEW Updates to the Living Treatment Guideline New recommendations Seven new treatment recommendations for pregnant and breastfeeding women Sotrovimab for pregnant women Following recent recommendations for the...
Communique

Communique #47

1 July, 2021
WEEK IN REVIEW Updates to the Living Treatment Guideline New recommendations Three new recommendations for the use of Casirivimab plus imdevimab (REGEN-COV) The Disease-Modifying Treatment and Chemoprophylaxis Panel...
Communique

Communique #45

3 June, 2021
Dear colleagues, On behalf of our 32 Taskforce members, we acknowledge our Victorian colleagues during another challenging and anxious time. Look after yourselves and each other, and we all hope an easing of...
Communique

Communique #44

24 May, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendations Baricitinib upgraded to a conditional recommendation The Disease-Modifying Treatment and Chemoprophylaxis Panel has reviewed the latest evidence for...
Communique

Communique #42

22 April, 2021
Message from the Chair and Executive Director Dear Colleagues We’ve just passed 12-months since the first publication of the Australian clinical guidelines for the care of people with COVID-19....
Communique

Communique #40

18 March, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendation for tocilizumab in children or adolescents Further to the Taskforce's recent recommendation for the conditional use of tocilizumab for adults (25...
Communique

Communique #39

25 February, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Tocilizumab upgraded to conditional recommendation The Taskforce Disease Modifying Treatment and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...
Communique

RECOVERY Trial publishes tocilizumab results

12 February, 2021
The Taskforce notes the publication of results of the tocilizumab arm of the RECOVERY trial in medRxiv Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results...
News

Weekly Communique #33

26 November, 2020
WEEK IN REVIEW Updates to the living guideline Three new recommendations have been published this week covering: Bamlanivimab Fluvoxamine Intravenous immunoglobulin VTE prophylaxis for children and adolescents Further details are...
Communique

Weekly Communique #29

29 October, 2020
WEEK IN REVIEW Updates to the living guideline this week New recommendations Three new recommendations have been published covering: Triazavirin Other immunomodulatory agents (PIMS-TS) Aspirin and antithrombotic agents...
Communique

Weekly Communique #16

30 July, 2020
Dear colleagues, On behalf of all members of the Taskforce, we would like to take this opportunity to acknowledge our Victorian colleagues caring for people with COVID-19 during...
Communique

Weekly Communique #11

25 June, 2020
WEEK IN REVIEW Dexamethasone now under review by the Taskforce Following Tuesday's (23 June) pre-print release of results of the dexamethesaone arm of the UK's RECOVERY study, the...
Communique

Weekly Communique #10

18 June, 2020
WEEK IN REVIEW Dexamethasone and RECOVERY Trial  Oxford University's media release detailing preliminary results from the dexamethasone arm of the RECOVERY Trial dominated international headlines. In response, the...
Communique

Weekly Communique #2

23 April, 2020
WEEK IN REVIEW The Consumers Health Forum (CHF) is an official community partner of the Taskforce. We met this week to develop a consumer engagement strategy; two consumer...
Communique